Glanbia plc (GLAPF)
| Market Cap | 6.17B +46.1% |
| Revenue (ttm) | 4.10B +3.8% |
| Net Income | 237.70M +96.8% |
| EPS | 0.97 +108.0% |
| Shares Out | n/a |
| PE Ratio | 25.98 |
| Forward PE | 15.78 |
| Dividend | 0.52 (1.91%) |
| Ex-Dividend Date | Aug 20, 2026 |
| Volume | 100 |
| Open | 27.00 |
| Previous Close | n/a |
| Day's Range | 27.00 - 27.00 |
| 52-Week Range | 15.99 - 28.81 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Glanbia
Glanbia plc, together with its subsidiaries, operates as a nutrition company worldwide. The company offers sports nutrition and lifestyle nutrition products in various formats, such as powders, capsules, tablets, ready-to-eat bars, and ready-to-drink beverage. It also manufactures and sells cheese, dairy, and non-dairy nutritional and functional ingredients; and vitamin and mineral premixes products. In addition, the company engages in the financing business; property and land dealing business; property leasing; provision of business services a... [Read more]
Financial Performance
In fiscal year 2025, Glanbia's revenue was $3.95 billion, an increase of 2.78% compared to the previous year's $3.84 billion. Earnings were $183.30 million, an increase of 11.29%.
Financial StatementsNews
Glanbia price target raised to EUR 21.80 from EUR 19 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Glanbia (GLAPF) to EUR 21.80 from EUR 19 and keeps an Equal Weight rating on the shares.
Glanbia hikes profit forecast as weight-loss drugs boost demand for protein products
Nutrition supplement maker Glanbia hiked its full-year profit forecast on Thursday following bumper demand for its protein products, including from customers using them in tandem with weight-loss dru...
Glanbia Earnings Call Transcript: H1 2026
Strong H1 2026 results featured 30% EPS growth and 7% revenue growth, driven by robust demand and margin expansion across all segments. Upgraded full-year guidance reflects continued momentum, with strategic investments and transformation savings supporting future growth.
Glanbia Quarterly report: H1 2026
Glanbia has published its H1 2026 quarterly earnings report on August 6, 2026.
Glanbia Slides: H1 2026
Glanbia has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 6, 2026.
Glanbia downgraded to Neutral from Outperform at Oddo BHF
Oddo BHF downgraded Glanbia (GLAPF) to Neutral from Outperform with a price target of EUR 24, up from EUR 21.80. The firm cites valuation following the recent share rally for…
Glanbia price target raised to EUR 26.50 from EUR 21.50 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Glanbia (GLAPF) to EUR 26.50 from EUR 21.50 and keeps a Buy rating on the shares.
Glanbia price target raised to EUR 19 from EUR 18.30 at Morgan Stanley
Morgan Stanley analyst David Roux raised the firm’s price target on Glanbia (GLAPF) to EUR 19 from EUR 18.30 and keeps an Equal Weight rating on the shares. Published first…
Glanbia price target raised to EUR 24 from EUR 20 at Barclays
Barclays raised the firm’s price target on Glanbia (GLAPF) to EUR 24 from EUR 20 and keeps an Overweight rating on the shares.
Glanbia price target raised to EUR 21.50 from EUR 18.50 at Deutsche Bank
Deutsche Bank analyst Damian McNeela raised the firm’s price target on Glanbia (GLAPF) to EUR 21.50 from EUR 18.50 and keeps a Buy rating on the shares. Published first on…
Glanbia price target raised to EUR 18.30 from EUR 18 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Glanbia (GLAPF) to EUR 18.30 from EUR 18 and keeps an Equal Weight rating on the shares.
Glanbia Earnings Call Transcript: Q1 2026
Group revenue rose 7.2% like-for-like, led by double-digit growth in Performance Nutrition and Health & Nutrition. Adjusted EPS is now expected at the upper end of guidance, with strong demand, price increases, and efficiency gains offsetting input cost pressures.
Glanbia Slides: Q1 2026
Glanbia has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Glanbia Earnings release: Q1 2026
Glanbia released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Glanbia price target lowered to EUR 18 from EUR 18.20 at Morgan Stanley
Morgan Stanley analyst David Roux lowered the firm’s price target on Glanbia (GLAPF) to EUR 18 from EUR 18.20 and keeps an Equal Weight rating on the shares. Published first…
Glanbia price target raised to EUR 21 from EUR 19 at Mizuho
Mizuho analyst John Baumgartner raised the firm’s price target on Glanbia (GLAPF) to EUR 21 from EUR 19 and keeps an Outperform rating on the shares. The firm views the…
Glanbia downgraded to Hold from Buy at Kepler Cheuvreux
Kepler Cheuvreux downgraded Glanbia (GLAPF) to Hold from Buy.
Glanbia downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Glanbia (GLAPF) to Equal Weight from Overweight with a price target of EUR 18.20, down from EUR 18.30. The firm says increasing whey input costs could drive…
Glanbia Earnings Call Transcript: H2 2025
Robust 2025 performance with revenue and volume growth across all segments, despite margin pressure from elevated whey costs. Strategic transformation, portfolio optimization, and capacity expansion underpin medium-term growth targets, with strong cash flow and shareholder returns.
Glanbia Annual report: H2 2025
Glanbia has published its H2 2025 annual report on February 25, 2026.
Glanbia Annual report: H2 2025
Glanbia has published its H2 2025 annual report on February 25, 2026.
Glanbia Slides: H2 2025
Glanbia has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 25, 2026.
Glanbia price target raised to EUR 18.80 from EUR 18.50 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Glanbia (GLAPF) to EUR 18.80 from EUR 18.50 and keeps an Overweight rating on the shares.
Glanbia price target lowered to EUR 18.50 from EUR 18.80 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Glanbia (GLAPF) to EUR 18.50 from EUR 18.80 and keeps an Overweight rating on the shares.
Glanbia Transcript: CMD 2025
Sharpened focus on performance and health nutrition drives ambitious growth targets, with innovation, global expansion, and operational efficiency at the core. Financial guidance includes 5%-7% annual organic revenue growth in performance nutrition, 4%-6% in health & nutrition, and a raised dividend payout ratio.